TrialBlood advances2024
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.
Sarah Nikiforow et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papercites it
TrialBlood advances2024
Sarah Nikiforow et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.